Literature DB >> 24735016

Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.

Sara Raponi1, Irene Della Starza, Maria S De Propris, Ilaria Del Giudice, Francesca R Mauro, Marilisa Marinelli, Valeria Di Maio, Alfonso Piciocchi, Robin Foà, Anna Guarini.   

Abstract

Minimal residual disease (MRD) is becoming increasingly important in chronic lymphocytic leukaemia (CLL) as treatment strategies are progressively improving. The primary objective of this study was to compare the applicability of three different flow cytometric approaches: basic 4-colour analysis, European Research Initiative in CLL (ERIC) consensus method and 8-colour analysis. Secondly, we investigated the sensitivity and specificity of flow cytometry (FC) compared to molecular analyses for MRD detection. A total of 462 CLL samples were evaluated by basic FC; in 143, ERIC consensus method was also performed and all three FC methodologies were applied in a subgroup of 10 cases. No discordance in defining MRD-positive/negative samples was observed between the FC methods; within positive samples, the ERIC consensus method and 8-colour analysis showed the most accurate results. MRD was analysed by FC and polymerase chain reaction (PCR) in 243 cases: concordant results were obtained in 199/243 samples (81·9%); 42/243 were FC-/PCR+. Overall, the sensitivity and specificity of FC compared to PCR was 96·5% and 77·2%, respectively. Both FC and PCR proved suitable for the detection of MRD and prediction of progression-free survival, which was significantly reduced in MRD-positive patients, regardless of the methodology. These results offer the rationale for a strategy to monitor MRD in CLL patients.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  ASO IgH RQ-PCR; chronic lymphocytic leukaemia; flow cytometry; minimal residual disease

Mesh:

Substances:

Year:  2014        PMID: 24735016     DOI: 10.1111/bjh.12887

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

2.  Relapsed disease and aspects of undetectable MRD and treatment discontinuation.

Authors:  Barbara Eichhorst; Moritz Fürstenau; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.

Authors:  Mazyar Shadman; Ajay K Gopal; Britt Kammerer; Pamela S Becker; David G Maloney; Barbara Pender; Andrei R Shustov; Oliver W Press; John M Pagel
Journal:  Leuk Lymphoma       Date:  2015-08-28

Review 4.  Prognostic Factors for Chronic Lymphocytic Leukemia.

Authors:  Christopher Chen; Soham Puvvada
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

5.  Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting.

Authors:  Shimrit Ringelstein-Harlev; Riva Fineman
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

6.  Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.

Authors:  Celso Arrais Rodrigues; Matheus Vescovi Gonçalves; Maura Rosane Valério Ikoma; Irene Lorand-Metze; André Domingues Pereira; Danielle Leão Cordeiro de Farias; Maria de Lourdes Lopes Ferrari Chauffaille; Rony Schaffel; Eduardo Flávio Oliveira Ribeiro; Talita Silveira da Rocha; Valeria Buccheri; Yuri Vasconcelos; Vera Lúcia de Piratininga Figueiredo; Carlos Sérgio Chiattone; Mihoko Yamamoto
Journal:  Rev Bras Hematol Hemoter       Date:  2016-08-20

7.  Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.

Authors:  Stephan Stilgenbauer; Veronique Leblond; Robin Foà; Sebastian Böttcher; Osman Ilhan; Wolfgang Knauf; Eva Mikuskova; Christoph Renner; Eugen Tausch; Dariusz Woszczyk; Ekaterina Gresko; Linda Lundberg; Tom Moore; Thea Morris; Susan Robson; Francesc Bosch
Journal:  Leukemia       Date:  2018-04-27       Impact factor: 11.528

Review 8.  Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

Authors:  Moritz Fürstenau; Nisha De Silva; Barbara Eichhorst; Michael Hallek
Journal:  Hemasphere       Date:  2019-08-09

Review 9.  Measurable residual disease in the treatment of chronic lymphocytic leukemia.

Authors:  Takayoshi Uchiyama; Aki Yokoyama; Sadao Aoki
Journal:  J Clin Exp Hematop       Date:  2020-11-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.